Speakers:
- Benedikt Huttner, Unit Head – Research, Access, Stewardship and AMR surveillance, Department of Antimicrobial Resistance, World Health Organization (Switzerland)
- Paul Feurstadt, Attending Physician, PACT Gastroenterology Center, Associate Clinical Professor of Medicine, Yale School of Medicine (USA)
- Kerrie Davies, Consultant Clinical Scientist, NIHR Leeds Biomedical Research Center (UK)
- Mark Wilcox, Professor of Medical Microbiology, University of Leeds (UK)
Moderator:
- Christian John Lillis, Chief Executive Officer, Peggy Lillis Foundation (USA)
Presentation 1: Global epidemiology of Clostridioides difficile and WHO priorities for prevention (Benedikt Huttner)
- Summary of what is known about the global epidemiology of Clostridioides difficile, including burden, geographical variation, and remaining surveillance gaps—particularly in low and middle-income countries.
- An overview of current treatment options and challenges, including recurrence, disparities
- Implications for antimicrobial stewardship (AMS), highlighting how antibiotic exposure drives C. difficile risk, and what this means for global AMS priorities and implementation.
Presentation 2: Pathophysiology of Clostridioides difficile infection – implications for treatment (Paul Feurstadt)
- Understanding the pathophysiology of C. difficile infection
- Understanding recurrent disease and treatment options
- Discussing the unmet need for treatment of recurrent C. difficile infection
Presentation 3: Updates on diagnosis (Kerrie Davies)
- Why is diagnosis difficult?
- What is the optimal laboratory diagnostic method?
- What’s new on the horizon?
Presentation 4: Pipeline of new therapies (Mark Wilcox)
- Pipeline therapeutics for Clostridioides difficile infection
- Pipeline prevention options for Clostridioides difficile infection
This webinar is being done in collaboration with the Peggy Lillis Foundation
This live webinar including an interactive Q&A session will be broadcast on 13 March 2026. You can find your timezone here.
If you have questions or comments, please let us know: revive@gardp.org.
